Tenderwize
Back to tender search

Bosutinib Discount Agreements

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Oct 05, 2026 · 49 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Bosutinib, ATC L01EA04

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

No guaranteed sales volume; discounts are purely contractual without minimum purchase obligations.

Agreements automatically terminate if a competitive discount agreement for Bosutinib is concluded at national or region...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2026
  • Non-exclusive discount agreements for Bosutinib (ATC L01EA04) pharmaceutical products
  • All interested pharmaceutical companies can join
Show full summary

The AOK Bayern is conducting an open-house model (not a competitive tender) to enter into non-exclusive discount agreements with all interested pharmaceutical companies for the active substance Bosutinib (ATC L01EA04) under § 130a Abs. 8 SGB V. The contract runs from 01.12.2024 to 30.11.2026, with the possibility of joining any time until 05.10.2026. No estimated value is provided. The procedure is outside procurement law; agreements are identical and non-negotiable. Eligibility is solely demonstrated via a signed self-declaration of reliability.

Risks

No guaranteed sales volume; discounts are purely contractual without minimum purchase obligations.

Agreements automatically terminate if a competitive discount agreement for Bosutinib is concluded at national or region...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer)

Administrative

  • Submit signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submit signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria; open-house model.

Buyer

Location

München, DEU

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Bosutinib Discount Agreements

Non-exclusive discount agreements for pharmaceutical products containing Bosutinib (ATC L01EA04). All interested pharmaceutical companies meeting eligibility can join. Contracts identical, not negotiable. Early start 01.12.2024, end 30.11.2026.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Nov 2024 - Nov 2026

Category

Pharmaceutical products

Award Criteria

No award criteria; open-house model.

Deadline

Deadline Oct 05, 2026

Procurement Details

Publication date
16 Oct 2024
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
628220-2024

Documents (2)

Similar tenders